Cell skeleton may hold key to overcoming drug resistance in cancerOctober 04, 2007
A team of scientists at Children's Cancer Institute Australia for Medical Research (CCIA), led by Associate Professor Maria Kavallaris, discovered that the bIII-tubulin component of the cell's cytoskeleton could play an important role in resistance to a wide range of drugs used to treat lung, ovarian and breast cancers.
Advanced non-small cell lung carcinomas (NSCLC) account for more than 80 per cent of lung cancer cases. More than one million people are diagnosed with lung cancer every year, the most common cancer in the world and the leading cause of cancer deaths. Chemotherapy remains the most effective treatment option, involving a diverse range of drugs, often used in combination. However, the emergence of drug-resistant tumours in NSCLC means chemotherapy no longer holds the promise of a good outcome for many patients.
Increased expression of bIII-tubulin has been linked to drug resistance in NSCLC, ovarian and breast cancers. In the latest Cancer Research publication, Associate Professor Kavallaris and her team showed that blocking the expression of the bIII-tubulin gene in NSCLC cells led to an increase in their sensitivity to a range of chemotherapeutic drugs.
"Our results strongly suggest that the bIII-tubulin component is responsible for protecting NSCLC cells from the action of key chemotherapeutic drugs," said Associate Professor Kavallaris.
"This is the first scientific evidence for the broader implications of abnormal expression of this protein.
"We now have new insight into a mechanism of drug resistance in NSCLC which has not previously been reported. This has important implications for improving the targeting and treatment of a number of cancers which are resistant to current chemotherapeutic drugs," said Associate Professor Kavallaris.
Related Chemotherapeutic Drug Current Events and Chemotherapeutic Drug News Articles
Innovative light therapy reaches deep tumors
Light long has been used to treat cancer. But phototherapy is only effective where light easily can reach, limiting its use to cancers of the skin and in areas accessible with an endoscope, such as the gastrointestinal tract.
CNIO associates rare gene variants with side effects from chemotherapy with paclitaxel
Paclitaxel is a chemotherapeutic drug that has been shown to be highly effective when treating solid tumours, such as breast, ovarian and lung tumours.
Major discovery on the mechanism of drug resistance in leukemia and other cancers
A mechanism that enables the development of resistance to Acute Myeloid Leukemia (AML) anticancer drugs, thereby leading to relapse, has been identified by Kathy Borden of the University of Montreal's Institute for Research in Immunology and Cancer (IRIC) and her collaborators.
Genetic aberration paves the way for new treatment of cancer disease
Researchers from Faculty of Health and Medical Sciences, University of Copenhagen, have characterized a genetic aberration on a group of colorectal cancer patients.
Nanotech system, cellular heating may improve treatment of ovarian cancer
The combination of heat, chemotherapeutic drugs and an innovative delivery system based on nanotechnology may significantly improve the treatment of ovarian cancer while reducing side effects from toxic drugs, researchers at Oregon State University report in a new study.
Celery, artichokes contain flavonoids that kill human pancreatic cancer cells
Celery, artichokes, and herbs, especially Mexican oregano, all contain apigenin and luteolin, flavonoids that kill human pancreatic cancer cells in the lab by inhibiting an important enzyme, according to two new University of Illinois studies.
More Effective Immunotherapy for Melanoma Hinges on Blocking Suppressive Factors, Moffitt Cancer Center Researchers Say
Researchers at the Moffitt Cancer Center have found that delayed tumor growth and enhanced survival of mice bearing melanoma were possible by blocking the reconstitution of myeloid-derived suppressor cells and Tregs (suppressors of anti-tumor activity) after total body irradiation had eliminated them.
CWRU School of Medicine researchers discover gene that permanently stops cancer cell proliferation
Researchers at Case Western Reserve University School of Medicine have discovered a mutant form of the gene, Chk1, that when expressed in cancer cells, permanently stopped their proliferation and caused cell death without the addition of any chemotherapeutic drugs.
Regulation by proteins outside cancer cells points to potential new drug target
Protein interactions outside breast cancer cells can send signals to the cancer cells to permanently stop proliferating, a new study showed in the School of Medicine at The University of Texas Health Science Center San Antonio.
Nanoparticles engineered at Notre Dame promise to improve blood cancer treatment
Researchers from the University of Notre Dame have engineered nanoparticles that show great promise for the treatment of multiple myeloma (MM), an incurable cancer of the plasma cells in bone marrow.
More Chemotherapeutic Drug Current Events and Chemotherapeutic Drug News Articles